Solid Biosciences Reports Inducement Grant to New Senior Vice President, Finance
Solid Biosciences Inc. (Nasdaq: SLDB) has announced the grant of inducement awards to its new Senior Vice President of Finance, Michael Inbar. This decision was approved by independent directors on July 27, 2021. The inducement grant includes options to purchase 118,000 shares of common stock and restricted stock units for 59,000 shares, both vesting over four years. The options have a ten-year term with an exercise price set at $2.51 per share, reflecting the closing price on August 16, 2021.
- Inducement awards granted to attract a key finance executive.
- Options to purchase 118,000 shares enhances executive alignment with shareholder interests.
- None.
CAMBRIDGE, Mass., Aug. 19, 2021 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB), a life sciences company focused on advancing meaningful therapies for Duchenne muscular dystrophy (Duchenne), today announced the grant of inducement awards to its newly appointed Senior Vice President, Finance, Michael Inbar. The grant was approved by a majority of the independent directors of the Company on July 27, 2021 as an inducement material to Mr. Inbar entering into employment with the Company in accordance with Nasdaq Listing Rule 5635(c)(4).
The inducement grant to Mr. Inbar consisted of an option to purchase up to 118,000 shares of common stock and a restricted stock unit award with respect to 59,000 shares of common stock. The option has a ten-year term and an exercise price of
About Solid Biosciences
Solid Biosciences is a life sciences company focused on advancing transformative treatments to improve the lives of patients living with Duchenne. Disease-focused and founded by a family directly impacted by Duchenne, our mandate is simple yet comprehensive – work to address the disease at its core by correcting the underlying mutation that causes Duchenne with our lead gene therapy candidate, SGT-001. For more information, please visit www.solidbio.com.
Investor Contact:
Caitlin Lowie
Solid Biosciences
607-423-3219
Clowie@solidbio.com
David Carey
FINN Partners
212-867-1768
David.Carey@finnpartners.com
Media Contact:
Erich Sandoval
FINN Partners
917-497-2867
Erich.Sandoval@finnpartners.com
FAQ
What is the purpose of the inducement awards granted to Michael Inbar at Solid Biosciences?
How many shares were included in the inducement grant for Michael Inbar?
What is the exercise price of the stock options granted to Michael Inbar?
When were the inducement grants to Michael Inbar approved?